Skin Safety Study to Evaluate the Sensitizing Potential in Healthy Volunteers

August 7, 2015 updated by: Maruho North America Inc.

A Phase 1, Randomized, Evaluator Blinded, Controlled Study to Evaluate the Sensitizing Potential of M518101 in Healthy Volunteers Using a Repeat Insult Patch Test Design

This is a single center, randomized, controlled, within subject comparison, multiple dose study to determine the sensitization potential of M518101 on normal skin under occlusive patch condition.

Study Overview

Detailed Description

During the Induction Phase of the study, the study drugs and controls will be applied 9 times for 21 days on the infrascapular area of the back under occlusive patch conditions.

Following induction, subjects will have a 10 to 14-day Rest phase, after which they will enter the challenge Phase, which consists of one 48-hour patch application (occlusive) to a naïve site on the opposite side of the back.

Study Type

Interventional

Enrollment (Actual)

240

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • New Jersey
      • Fair Lawn, New Jersey, United States, 07410
        • TKL Research

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Health male or female subjects are age 18 years or older
  • Signed and dated Informed Consent Form obtained prior to any study related activities
  • Subjects are free of any systemic or dermatologic disorder
  • For female, females of non childbearing potential or who agree to use a highly effective method of birth control during the study and have a negative urine pregnancy test
  • Subjects must be able to communicate with the investigator and understand and comply with the requirement of the study and visit schedule

Exclusion Criteria:

  • Have any visible skin disease at the application site which will interfere with the evaluation of the test site reaction
  • Have damaged skin in or around the test sites
  • Have a history of sensitivity to adhesive tape
  • Have a known sensitivity to constituents present in the material being evaluated
  • Have a history of, or are currently being treated for skin cancer
  • Have used any study drug and/or participate in any clinical study within 60 days prior to randomization
  • To engage in any type of strenuous exercise
  • Are pregnant, breastfeeding, or of childbearing potential and who wish to become pregnant during the study
  • Are deemed to be ineligible by the investigator

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Allocation: Randomized
  • Interventional Model: Single Group Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: M518101
M518101 will be applied 9 times for 21 days on the infrascapular area of the back under occlusive patch conditions.
Placebo Comparator: M518101 Vehicle
M518101 Vehicle will be applied 9 times for 21 days on the infrascapular area of the back under occlusive patch conditions.
Active Comparator: Sodium lauryl sulfate
The sodium lauryl sulfate will be applied 9 times for 21 days on the infrascapular area of the back under occlusive patch conditions.
Sham Comparator: Saline
The saline will be applied 9 times for 21 days on the infrascapular area of the back under occlusive patch conditions.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
inflammatory skin response score
Time Frame: 21 days
Drug application site will be evaluated for sign of inflammatory skin response (e.g. erythema, edema, papules)
21 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

September 1, 2014

Primary Completion (Actual)

November 1, 2014

Study Completion (Actual)

August 1, 2015

Study Registration Dates

First Submitted

September 30, 2014

First Submitted That Met QC Criteria

October 1, 2014

First Posted (Estimate)

October 6, 2014

Study Record Updates

Last Update Posted (Estimate)

August 11, 2015

Last Update Submitted That Met QC Criteria

August 7, 2015

Last Verified

August 1, 2015

More Information

Terms related to this study

Other Study ID Numbers

  • M518101-US07

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy Volunteers

Clinical Trials on Saline

3
Subscribe